Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Esophageal Neoplasms

Carcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Esophageal Diseases

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Cisplatin

Immunomodulating Agents

Nedaplatin

Tubulin Modulators

Antimitotic Agents

1. camrelizumab 200mg intravenous drip d1q3w
2. Paclitaxel: 150mg/m2 d1 q3w
3. Platinum: Cisplatin, carboplatin, nedaplatin and other platinum drugs
4. Radiotherapy dose: 5040cGy/28f radiotherapy efficacy evaluation after 2-3 cycles of chemotherapy PR/SD received local radiotherapy.

camrelizumab

Paclitaxel drugs

Cisplatin, carboplatin, nedaplatin and other platinum drugs

Platinum drug

Radiation

Jiancheng Li, Doctor

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma

ORR is determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.

Defined as the time from the enrollment to death from any cause

It is defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.

Fujian Cancer Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.	NCT05624099	Esophageal Neop... Esophageal Dise... Digestive Syste...	camrelizumab Paclitaxel drug... Platinum drug Radiation	18 Years - 75 Years	Fujian Cancer Hospital
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.	NCT05624099	Esophageal Neop... Esophageal Dise... Digestive Syste...	camrelizumab Paclitaxel drug... Platinum drug Radiation	18 Years - 75 Years	Fujian Cancer Hospital

Spots Global Cancer Trial Database for paclitaxel drugs